Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › quizartinib

quizartinib

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of quizartinib

9 trials tracked of quizartinib: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 478 citations.

9Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 2 Phase 1 5
  1. Phase 3 (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive Completed · 478 cited
  2. Phase 3 Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) Completed · 358 cited
  3. Phase 2 Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed
  4. Phase 2 Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation Completed
  5. Phase 1 Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Completed
  6. Phase 1 A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects Completed
Show 3 more trials
  1. Phase 1 A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants Completed
  2. Phase 1 A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants Completed
  3. Phase 1 A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment Completed

Showing the 9 most-cited and recently-updated of 9 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network Meta-Analysis Compares FLT3 Inhibitors in Acute Myeloid Leukemia
Oncology Meta-analysis
Network Meta-Analysis Compares FLT3 Inhibitors in Acute Myeloid Leukemia Three FLT3 inhibitors show promise for AML patients
This network meta-analysis of 6128 acute myeloid leukemia patients compared FLT3 inhibitors. Gilteritinib and midostaurin improved complete …
Gilteritinib and midostaurin boost remission rates; gilteritinib and quizartinib improve survival in AML.
Frontiers May 11, 2026
FDA Approves Vanflyta (quizartinib) for Newly Diagnosed FLT3-ITD-Positive AML in Adults
Oncology FDA Approval
FDA Approves Vanflyta (quizartinib) for Newly Diagnosed FLT3-ITD-Positive AML in Adults FDA approves new drug called Vanflyta for a specific type of blood cancer in adults
Vanflyta is approved in combination with induction and consolidation chemotherapy, and as maintenance monotherapy, for adult patients with n…
FDA approves Vanflyta to treat acute myeloid leukemia in adults with a specific genetic change that makes the cancer harder to manage.
FDA Apr 16, 2026
Phase II trial compares quizartinib vs placebo with chemotherapy in FLT3 wild-type AML
Hematology Phase II
Phase II trial compares quizartinib vs placebo with chemotherapy in FLT3 wild-type AML Can adding quizartinib to standard chemo help adults with a common type of acute myeloid leukemia?
A randomized phase II trial compared standard chemotherapy plus quizartinib versus standard chemotherapy plus placebo in 273 adults with new…
Adding quizartinib to standard chemotherapy for newly diagnosed acute myeloid leukemia aims to help patients live longer without their cance…
CT.gov Mar 30, 2026